Transcript Dias nummer 1

Five phase 3 trials will collaborate internationally to answer 4
major questions in the management of endometrial cancer:
• Does proper lymphadenectomy improve survival?
LYTEC Trial & AGO-ECLAT trial
• Is there a need for adjuvant chemotherapy in node negative
high-risk early stage patients?
ENGOT-EN2-DGCG trial
• Is adjuvant chemo followed by RT better than chemo alone
in high-risk nodal status unknown early stage or stage 3 patients?
NSGO trial
•
Can combination of standard chemotherapy with targeted therapy
compared to combination chemotherapy alone improve disease control
rate of advanced or chemo-naïve relapsed endometrial cancer?
AGO/NOGGO trial
Adjuvant Endometrial Cancer Trial
[email protected]
ENGOT-NESTEC: NEtwork STudy in Endometrial Cancer
under the ENGOT umbrella and in cooperation with the Mayo clinic.
Clinically presumed: FIGO IB-II any histo type, FIGO
I A G3 endometroid, FIGO IA/B histo type II
R
R
surgery
R
R
No bulky LN
Bulky LN
In OP
LNE
R
NLNE*
N-
AGO/NOGGO trial (Sehouli)
DGCG trial (Mirza)
FIGO III not Ro and pos. LN or cytology
only; FIGO IV
Recurrent FIGO I/II
N+
R
no LNE
N+
Standard arm:
Carbo-paclitaxel
+ Placebo
R
Chemo 1
Carbo-paclitaxel
R
Chemo +.
Radiotherapy
observation
Mayo trial (Dowdy, Mariani)
AGO ECLAT trial (Emons)
NSGO trial (Hogberg)
Chemo 1
Carbo-paclitaxel
Experim. arm:
Carbo-paclitaxel
+ mTOR inhibitor